Details

Autor(en) / Beteiligte

• Némati, Fariba
• Sastre-Garau, Xavier
• Laurent, Cécile
• Couturier, Jérôme
• Mariani, Pascale
• Desjardins, Laurence
• Piperno-Neumann, Sophie
• Lantz, Olivier
• Asselain, Bernard
• Plancher, Corine
• Robert, Delphine
• Péguillet, Isabelle
• Donnadieu, Marie-Hélène
• Dahmani, Ahmed
• Bessard, Marie-Andrée
• Gentien, David
• Reyes, Cécile
• Saule, Simon
• Barillot, Emmanuel
• Roman-Roman, Sergio
• Decaudin, Didier

Titel

Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors

Ist Teil von

• Clinical cancer research, 2010-04, Vol.16 (8), p.2352-2362

Ort / Verlag

United States

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Uveal melanoma is the most common primary intraocular malignant tumor in adults and is defined by a poor natural outcome, as 50% of patients die from metastases. The aim of this study was to develop and characterize a panel of human uveal melanoma xenografts transplanted into immunodeficient mice. Ninety tumor specimens were grafted into severe combined immunodeficient mice, and 25 transplantable xenografts were then established (28%). Relationship between tumor graft and clinical, biological, and therapeutic features of the patients included were investigated. Characterization of 16 xenografts included histology, molecular analyses by immunohistochemistry, genetic alteration analysis (single-nucleotide polymorphism), and specific tumor antigen expression by quantitative reverse transcription-PCR. Pharmacologic characterization (chemosensitivity) was also done in four models using two drugs, temozolomide and fotemustine, currently used in the clinical management of uveal melanoma. Take rate of human uveal melanoma was 28% (25 of 90). Tumor take was independent of size, histologic parameters, or chromosome 3 monosomy but was significantly higher in metastatic tumors. Interestingly, in vivo tumor growth was prognostic for a lower metastasis-free survival in patients with primary tumors. A high concordance between the patients' tumors and their corresponding xenografts was found for all parameters tested (histology, genetic profile, and tumor antigen expression). Finally, the four xenografts studied displayed different response profiles to chemotherapeutic agents. Based on these results, this panel of 16 uveal melanoma xenografts represents a useful preclinical tool for both pharmacologic and biological assessments.